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Abstract 
Rich meta-epidemiological data sets have been collected to explore associations between intervention 
effect estimates and study-level characteristics. Welton et al. proposed models for the analysis of 
meta-epidemiological data, but these models are restrictive because they force heterogeneity among 
studies with a particular characteristic to be at least as large as that among studies without the 
characteristic. In this paper we present alternative models that are invariant to the labels defining the 
two categories of studies.  To exemplify the methods, we use a collection of meta-analyses in which 
the Cochrane Risk of Bias tool has been implemented. We first investigate the influence of small trial 
sample sizes (less than 100 participants), before investigating the influence of multiple 
methodological flaws (inadequate or unclear sequence generation, allocation concealment and 
blinding).  We fit both the Welton et al. model and our proposed label-invariant model and compare 
the results.  Estimates of mean bias associated with the trial characteristics and of between-trial 
variances are not very sensitive to the choice of model.  Results from fitting a univariable model show 
that heterogeneity variance is, on average, 88% greater among trials with less than 100 participants.  
Based on a multivariable model, heterogeneity variance is, on average, 25% greater among trials with 
inadequate/unclear sequence generation, 51% greater among trials with inadequate/unclear blinding, 
and 23% lower among trials with inadequate/unclear allocation concealment, though the 95% 
intervals for these ratios are very wide.  Our proposed label-invariant models for meta-
epidemiological data analysis facilitate investigations of between-study heterogeneity attributable to 
certain study characteristics.   
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1.  Introduction 
 
Meta-analysis is used to combine the results of multiple studies in order to synthesise evidence in a 
specific research area.  Variation in effect sizes among studies, known as heterogeneity, is widespread 
and reflects differences in design and conduct of the studies, as well as differences in the 
  
 
characteristics of participants, interventions and outcomes studied.  Possible explanations of 
heterogeneity among studies in a meta-analysis should be determined where possible.  Meta-analysts 
may explore heterogeneity by separating studies into subgroups, using meta-regression or restricting 
analyses to studies with particular characteristics.  However, results from such analyses are imprecise 
if the number of studies is small.   On the other hand, combining all available studies, while ignoring 
differences in their design and conduct, may produce results that are difficult to interpret or, at worst, 
meaningless. 
 
Meta-epidemiology is an emerging field of research that seeks to understand causes of heterogeneity 
across studies by re-analysing large numbers of meta-analyses. A notable example of a meta-
epidemiological study is the BRANDO study [1], which combined data from several existing meta-
epidemiological studies into a single database.  Each of the 1973 included trials was categorised 
according to whether specific design characteristics were judged to be adequate, inadequate or 
unclear.  Comparisons of trials in different categories were made within each of the meta-analyses, 
and these comparisons were combined across the 234 included meta-analyses. The results showed 
that, on average, effects were exaggerated in favour of the experimental treatment in trials judged not 
to have adequate sequence generation, allocation concealment and blinding.   
 
The analysis of BRANDO followed methods proposed by Welton et al.[2], which model the biases 
that may arise due to particular design characteristics within a Bayesian framework. Specifically, a 
bias parameter is introduced for effect sizes in studies with a particular design characteristic such as 
inadequate allocation concealment, and a hierarchical model structure is assumed for these, with 
variability in bias assumed across the studies with the characteristic within each meta-analysis and 
across meta-analyses. While intuitively appealing, a limitation of these models is that they impose an 
additive relationship between the amount of heterogeneity in the groups of studies, such that the 
studies with the characteristic are constrained to be at least as heterogeneous as the studies without the 
characteristic [3]. The inherent assumption that studies without the characteristic will be no more 
heterogeneous than studies with the characteristic will not necessarily be true.  Furthermore, when 
meta-epidemiological methods are used to examine study characteristics that are not clearly 
associated with methodological quality (such as single centre versus multicentre studies), the model is 
problematic because it forces a somewhat arbitrary assumption that the heterogeneity in one category 
is at least as large as that in the other category. In short, the model is not invariant to the labels 
defining the two categories of studies. 
 
In this paper, we present general models for the analysis of meta-epidemiological studies that are 
label-invariant. We allow variation among the studies with the characteristic of interest to be higher or 
lower than the variation among the studies without the characteristic. We achieve this by modelling a 
  
 
multiplicative rather than an additive relationship between the variance components in the two 
categories of studies. After introducing this model for a univariable model for combining studies with 
and without a single reported characteristic, we generalise our approach to a multivariable model for 
combining studies that differ according to multiple characteristics.  We then apply models with 
additive and label-invariant variance structures to a new meta-epidemiological dataset (the ROBES 
study), to investigate how estimates of average intervention effect and heterogeneity may depend on 
the choice of model.  We assess the robustness of results from the proposed label-invariant model to 
the choice of prior distribution for the multiplicative parameter in section 6.   
 
2. Univariable models to examine the influence of a single characteristic 
 
We first describe models for meta-epidemiological studies involving a single characteristic, to 
investigate differences due to one particular attribute of the studies, such as an aspect of design or 
quality.  In a given meta-analysis m, suppose that studies are categorised according to the presence or 
absence of the characteristic of interest.  We assume that each study i without the characteristic 
(denoted ‘−’) provides an estimate of the underlying intervention effect imθ
− .  We assume a normal 
random-effects distribution for the −imθ  with mean dm and variance 
2
mτ , specific to meta-analysis m: 
− 2
im m mθ ~N(d ,τ ) . 
 
A study with the characteristic (denoted ‘+’) is assumed to estimate an underlying intervention effect
imθ
+ .  In the additive model proposed by Welton et al., we define this to be a potentially biased version 
of what would have been estimated in the absence of the characteristic:  
+ −= +im im imθ θ β . 
 
A hierarchical structure is placed on the bias terms, imβ :  
2~ ( , )β κim m mN b , 
where bm and 2mκ  represent the mean and variance in bias, within meta-analysis m, associated with 
presence of the characteristic. We use Model 3 of Welton et al., assuming throughout that the variance 
in the biases is the same within each meta-analysis, such that 2 2=mκ κ  for all m. The assumption is 
not necessary, but there is seldom sufficient evidence to estimate multiple variance parameters. Thus 
the imθ
+  are assumed to be normally distributed as 
+ 2 2
im m m mθ ~N(d +b , τ +κ ). 
 
  
 
Note that the consequence of the hierarchical model structure for the within-study biases is that the 
variance of the imθ
+  is constrained to be at least as high as the variance of the imθ
− . We will refer to this 
as an additive variance structure. This could be particularly problematic because the estimated 
variance components in Bayesian hierarchical models have been shown to be biased upwards [4].   
For this reason, it may appear that the variance componentκ  is strictly positive, even though it is not. 
 
We propose an alternative, label-invariant, model, in which we allow the variance of the imθ
+  to be 
higher or lower than the variance of the imθ
− , by using a positive scale parameter, λ : 
+ 2
im m m mθ ~N(d +b , λτ ) . 
 
In the new model, λ  represents the ratio of the between-study heterogeneity among ‘+’ studies with 
the characteristic of interest, compared with ‘−’ studies without the characteristic.  Thus, when λ  
exceeds 1 the ‘+’ studies show greater between-study variability than the ‘−’ studies. 
 
For both the Welton model and our proposed label-invariant model, the mean bias bm associated with 
the characteristic of interest in meta-analysis m is assumed to be exchangeable across meta-analyses, 
with overall mean b0 and between-meta-analysis variance in mean bias 2φ : 
2
0b ~N(b , φ ).m  
 
Note that because our model is invariant to whether the characteristic is present or absent, the bm and 
b0 terms can be thought of simply as differences rather than as biases.  Parameters b0, φ and κ or λ are 
estimated through fitting these models to a meta-epidemiological dataset.  
 
3. Multivariable models to examine the influence of multiple characteristics 
 
Suppose now that studies in each pair-wise meta-analysis m have been categorised according to the 
presence of p reported characteristics, again representing differences in design or quality.  We set the 
indicator Xijm to be 1 for studies with the j-th reported characteristic (j=1,2,…,p), and 0 for studies 
without that characteristic.   
 
Multivariable models are based on extensions of the hierarchical models described in section 2.   
In the additive multivariable model, the studies with characteristic j (studies with Xijm=1) are assumed 
to estimate the same underlying intervention effect as the studies without this characteristic (studies 
with Xijm=0) plus some study-specific, characteristic-specific bias β ijm .  In multivariable analyses 
  
 
presented for the BRANDO study [1], a generalised version of Welton et al’s model was fitted, 
assuming each study i to estimate an underlying intervention effect imθ : 
2
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In the label-invariant model, the studies are assumed to have underlying intervention effect: 
{ }1
pp
2
im im pim m ijm jm m ijm ijm j
j=1 j=1
θ |X ,...,X ~N(d + X b , τ (1-X )+X λ ).∑ ∏  
 
For example, the intervention effect θim  in a study i with characteristics 1 and 2 but not 3 would have 
a normal distribution with mean m 1m 2md +b +b  and variance 1 2
2
mτ λ λ . 
 
Under this model, we estimate the parameters representing the differences bm in between-study means 
and the ratios λj of between-study variances , for each of the p characteristics .   
 
For both models, the implied average bias (on the log odds ratio scale) in studies with any 
combination of study characteristics is estimated by the sum of the relevant fitted b0 terms 0j
j
b∑ .  In 
practice we might expect study characteristics to be correlated.  It would be possible to extend the 
multivariable models to include interactions between different study characteristics [1], but we do not 
explore interactions in this paper.   
 
4. Additional modelling of heterogeneity variance 
 
It is of interest to compare variance estimates from fitting the existing additive model and the 
proposed label-invariant model.  This is difficult because estimates of κ from the additive model and λ 
from the label-invariant model have different interpretations and are not directly comparable.  For this 
reason, we focus on estimates of heterogeneity variances 2mτ (among studies without the characteristic 
of interest) which have the same interpretation under the two different models.  These estimates are 
influenced by κ in the additive model and λ in the label-invariant model, and hence comparison of the 
distributions obtained under the two different models gives some indication of agreement between 
estimates of variance components. 
  
 
 
Between-study heterogeneity 2mτ  varies across meta-analyses m and is estimated in the additive and 
label-invariant models above.  However, in order to compare estimates of total (within meta-analysis) 
heterogeneity, we need to obtain some “typical” value of τ .  For this reason, we extend the models 
slightly to include a hierarchical structure for log( 2mτ ).  We follow the approach of Turner et al. [5] 
and model the underlying values of between-study variance 2mτ  in intervention effect among studies 
without the characteristic of interest, assuming these to follow a log-normal(μ, σ2) distribution.  A 
predictive distribution for the heterogeneity variance 2newτ  (among studies without the characteristic 
of interest) is obtained under the full Bayesian model: 
2
newτ ~log-normal (μ, σ
2). 
 
To summarise this distribution, we report a log-normal distribution fitted to the predictive distribution, 
using the posterior mean and standard deviation for log( 2newτ ).    
 
 
5. Applications 
 
We make use of a newly constructed database from the ROBES study [6].  This database comprises 
244 meta-analyses with completed Risk of Bias tables, extracted from the April 2011 issue of the 
Cochrane Database of Systematic Reviews (CDSR). For each trial in every meta-analysis, information 
is available on all items addressed by the Cochrane Risk of Bias tool [7].  Meta-analyses where 
numerical data were unavailable or where pooling was considered inappropriate were excluded.  The 
ROBES database also excluded meta-analyses comprising fewer than five trials.  One binary outcome 
meta-analysis from each eligible Cochrane review was included in the database, corresponding to a 
primary outcome where possible. 
 
Empirical evidence suggests that intervention effect estimates are exaggerated in smaller studies [8] 
and studies with flaws in their design and conduct [1;6].  As an example application of the univariable 
models, we investigate the influence of small study sample sizes (less than 100 participants), before 
using multivariable models to investigate the influence of multiple methodological flaws (inadequate 
or unclear sequence generation, allocation concealment and blinding).   
 
In all analyses, intervention effects were modelled as log odds ratios and outcomes were coded so that 
a log odds ratio less than 0 corresponded to a beneficial intervention effect.  We assumed the observed 
number of events in each arm of each trial to have a binomial distribution. A vague normal(0,1000) 
  
 
prior was assigned to all location parameters.  Estimated mean differences b0 in intervention effect 
between trials with and without the characteristic of interest were exponentiated and are therefore 
reported as relative odds ratios (ROR).  Meta-analyses may be informative for some, but not all, 
reported characteristics.  We refer to meta-analyses as informative for a characteristic if they 
contained at least one trial with the characteristic and one without the characteristic and could inform 
estimation of average differences in intervention effect bm associated with the characteristic.   
 
In the additive models, variance parameters 2κ and ϕ 2  were given modified inverse-
gamma(0.001,0.001) prior distributions with a probability atom at zero variance, following Savovic et 
al. [1].  That is, we let the variance parameters 2κ and ϕ 2  be equal to zero with some probability p0 
and equal to the variance from an inverse-gamma prior with probability (1− p0). The mixing 
probability p0 was given an uninformative Beta(1,1) prior.  For the additional modelling of 
heterogeneity variances, we placed a vague prior on the mean, μ, and assumed a uniform(0,2) prior for 
the standard deviation parameter σ, representing variation in heterogeneity across meta-analyses, as 
suggested by Spiegelhalter et al. [9].  Posterior summaries from all models were obtained by using 
Markov chain Monte Carlo (MCMC) methods within WinBUGS Version 1.4.3 [10].  In order to 
produce very low MC error rates, we based results on 500,000 iterations, following a burn-in period 
of 25,000 iterations which was sufficient to achieve convergence.  Convergence was assessed 
according to the Brooks-Gelman-Rubin diagnostic tool [11], with three chains starting from widely 
dispersed initial values.   
 
In the label-invariant models, we placed a log-normal(0,1) prior distribution on the multiplicative 
parameters λ , which has median 1 on the untransformed scale.  We assess sensitivity to this choice of 
prior distribution in section 6.  Since it was not possible to compute both mτ  and κ  or λ  in a meta-
analysis with fewer than two trials with and without a characteristic of interest, such meta-analyses 
were not allowed to contribute to the estimation of κ  in the additive models or to the estimation of λ 
in the label-invariant models through use of the “cut” function in WinBUGS.   
 
In multivariable analyses we used WinBUGS to calculate a 95% credible interval for the implied 
average bias in trials with any combination of study characteristics, 0j
j
b∑ , that accounted for 
correlations between the coefficients b0j.   
 
Model fit comparison was based on the deviance information criterion (DIC)  [12;13].  The posterior 
mean of the total residual deviance Dres was used to assess the goodness-of-fit of the hierarchical 
models.  The DIC provides a measure of model fit that penalizes Dres by the effective number of 
  
 
parameters pD.  Due to the non-linearity between the likelihood and the model parameters, we 
calculated pD at the posterior mean of the fitted values rather than at the posterior mean of the 
parameters [14].   
 
The WinBUGS code for the label-invariant models presented in the paper is available in Supporting 
Information. 
  
5.1 Example 1: Univariable analyses examining the influence of sample size less than 100 
 
Sample size can vary substantially among studies, even within a single meta-analysis addressing the 
same research question [15].  Dechartres et al. investigated the influence of trial sample size on 
treatment effect estimates in a large collection of meta-analyses of various medical conditions and 
interventions [8].  Effect estimates differed within meta-analyses according to trial sample size; on 
average, stronger estimates were observed in small to moderately sized studies than in the largest 
studies.  Here we apply univariable models to examine the influence of trial sample sizes of less than 
100 participants on intervention effect and between-trial heterogeneity.  This fixed threshold for 
sample size has been chosen because it is approximately the median sample size of trials included in 
the ROBES database; our intention is to exemplify the methods rather than to provide empirical 
evidence. 
 
We analysed data from 2091 trials included in 179 binary outcome meta-analyses that were 
informative to detect differences in intervention effect between trials with sample size less than 100 
participants and those with larger sample sizes.  The number of trials per meta-analysis ranges from 5 
to 75 with median 9 and IQR 6 to 13.  The number of trials per meta-analysis with less than 100 
participants ranges from 1 to 29 with median 4 and IQR 2 to 7. 
 
Posterior summaries derived from the additive model are reported in Table 1.  Intervention effects 
were exaggerated by an average of 15% in trials with sample sizes of less than 100 (ROR 0.85, 95% 
credible interval (CI): 0.76 to 0.93).  The posterior median of the between-trial within-meta-analysis 
standard deviation κ  is 0.22 (95% CI: 0.02 to 0.40), and the between-meta-analysis standard 
deviation in mean bias ϕ  has posterior median 0.22 (95% CI: 0.03 to 0.36).  We derived a predictive 
log-normal(-2.94, 1.692) distribution for between-trial variance 2newτ  expected among trials with a 
sample size of at least 100 participants.  This predictive distribution has median 0.05 and 95% range 
0.002 to 1.42.   
 
  
 
Table 1 also provides the posterior summaries obtained from the label-invariant model. Estimated 
mean bias is fairly robust to the choice of variance structure, as is the estimated between-meta-
analysis standard deviation in mean bias ϕ .   In the label-invariant model, λ has posterior median 1.88 
(95% CI: 1.08 to 3.10), indicating that variation among trials with sample sizes less than 100 is on 
average 88% greater than that among trials with at least 100 participants.  The predictive distribution 
obtained for the between-trial heterogeneity variance 2newτ  expected among trials with at least 100 
participants is fairly similar to that obtained under the additive model, but gives less support to higher 
levels of heterogeneity.   
 
Values of Dres and pD for the additive model are close to those for the label-invariant model (Table 1).  
The label-invariant model has a lower DIC, but the difference in DIC between the additive and label-
invariant models is less than 5 and hence not considered to be meaningful [12].  We therefore have 
little reason to choose one model over the other.   
 
To confirm the label-invariant property of our proposed model, we inverted the sample size labels of 
the trials and applied the univariable models to examine the influence of trial sample sizes greater 
than 100 participants on intervention effect and between-trial heterogeneity.  Parameter estimates are 
shown in Table 2.  As expected, estimated mean bias b0 is the negative of the estimate obtained before 
re-labelling the trials.  Under the additive model, between-trial heterogeneity (quantified by κ) is 
constrained to be higher for trials with greater than 100 participants; the posterior median of κ is 0.03 
(95% CI: 0.01 to 0.09), which is lower than the posterior median 0.22 in Table 1.  Under the label-
invariant model, the posterior median of λ is 0.53 (95% CI: 0.32 to 0.85), which is approximately the 
reciprocal of the posterior median 1.88 obtained before relabelling the trials.  After re-labelling the 
trials, we find that the label-invariant model gives a better fit (lower Dres and DIC) and is preferred 
over the additive model.   
 
Although the same label-invariant model is used in each analysis reported in Tables 1 and 2, we make 
different assumptions about the distributional form of heterogeneity variances by relabelling the trials.  
For example, in the first analysis comparing smaller vs. larger studies (Table 1), heterogeneity 
variance for larger trials with greater than 100 participants is τ2, which is assumed to have a log-
normal distribution.  After re-labelling the trials, heterogeneity variance among larger trials is λτ2+φ2, 
which is not log-normal.  As a consequence, model fit may differ between the two analyses; here, we 
find that the label-invariant model gives a better fit (lower Dres and DIC) after re-labelling the trials.  
 
5.2 Example 2: Multivariable analyses examining the influence of inadequate or unclear 
sequence generation, allocation concealment and blinding. 
  
 
 
When conducting a systematic review, it is important to consider the risk of bias in the results of 
included studies. Including biased studies with methodological flaws in a meta-analysis will cause the 
results of the meta-analysis to be biased.  Differences in risks of bias can help explain variation in the 
results of the studies.   We conducted multivariable analyses to examine the influences of inadequate or 
unclear sequence generation, allocation concealment and blinding, compared with adequate, on 
combined intervention effect and between-trial heterogeneity.  Table 3 presents results from these 
analyses, based on 117 informative meta-analyses (1473 trials) in which all three design 
characteristics were assessed.  The number of trials per meta-analysis ranges from 5 to 75 with 
median 10 and IQR 6 to 14.  In 396 (27%) trials, all three design characteristics were judged as 
inadequate or unclear.  All three design characteristics were assessed as adequate in 361 (24%) trials.   
 
Posterior summaries from the multivariable additive model are shown in Table 3.  After adjusting for 
allocation concealment and blinding, intervention effects were exaggerated by 5% on average in trials 
with inadequate or unclear sequence generation (ROR 0.95, 95% CI: 0.87 to 1.04).  There is evidence 
that between-trial heterogeneity (quantified by 1κ ) is increased for trials with inadequate or unclear 
sequence generation; the posterior median of the additional between-trial within-meta-analysis 
standard deviation 1κ  is 0.12 (95% CI: 0.02 to 0.26).  For inadequate or unclear allocation 
concealment, the ROR has posterior median 0.96 with standard deviation 0.04, while 2κ  has posterior 
median 0.06 (95% CI: 0.01 to 0.20) after adjustment for sequence generation and blinding.  
Inadequate or unclear blinding was associated with an average 8% exaggeration of intervention effect 
estimates (ROR 0.92, 95% CI: 0.85 to 0.99) and with increased heterogeneity ( 3κ  0.08, 95% CI: 0.01 
to 0.27) after adjustment for sequence generation and allocation concealment.  The posterior estimates 
for mean bias imply an average bias of 0.84 (95% range: 0.76 to 0.92), on the relative odds ratio scale, 
for a trial judged as inadequate or unclear for all three bias domains. 
 
Table 3 also gives the posterior summaries obtained under the proposed label-invariant model. 
Estimates for mean bias b0j are not very sensitive to the choice of variance structure.  We find that 
estimates of between-meta-analysis standard deviation jϕ  in mean bias are comparable to those 
obtained using the additive model.   
 
In the label-invariant model, the posterior median for λ1 indicates that variation among trials with 
inadequate or unclear sequence generation is on average 25% greater than that among trials with 
adequate sequence generation.  Heterogeneity among trials judged as inadequate or unclear for 
allocation concealment is on average 77% of that among trials assessed as low risk of bias due to 
allocation concealment.  The central estimate for λ3 suggests that variation among trials with 
  
 
inadequate or unclear blinding is on average 51% greater than that among trials with adequate 
blinding.  However, we note that each λj is imprecisely estimated in the multivariable label-invariant 
model; the 95% credible intervals for λj are wide and contain the null value 1 representing no 
difference.   
 
The predictive distributions obtained for the between-trial variance 2newτ  expected to remain after 
“removing” bias due to inadequate or unclear sequence generation; allocation concealment and 
blinding are similar under the two models.   
 
In this example, we find that the additive model gives a better fit (lower Dres and DIC) and is preferred 
over the label-invariant model. 
 
6.  Assessing the sensitivity of results to the choice of prior for the multiplicative parameter λ 
 
Here we assess the sensitivity of posterior inferences from the label-invariant meta-epidemiological 
analyses to the choice of prior distribution for λj .  We re-analysed data from the 117 meta-analyses 
which were informative for bias due to inadequate/unclear sequence generation, allocation 
concealment and blinding.  We examined five realistic candidate vague priors for parameters λj  
(Figure 1).  Priors 1 to 4 are centred about the null value 1 representing no difference in heterogeneity 
among trials judged as adequate for all three bias domains and trials judged as inadequate or unclear 
for design characteristic j.  Prior 5 (truncated log-normal) gives support to values of  λj  strictly 
greater than 1, therefore mimicking the existing additive model for meta-epidemiological data 
analysis.  This prior has median 1.96 and 95% range 1.03 to 9.40.  Although each prior distribution is 
considered to be vague, each represents different beliefs about the likely ratio by which between-trial 
heterogeneity changes for trials with inadequate/unclear design characteristics.  For example, a 
uniform prior distribution for log( λj ) assigns equal weight to all values in the chosen range, giving 
no preference to certain values.  In contrast, a normal prior distribution for log( λj ) gives greater 
support to values of log( λj ) closer to the centre of the distribution, therefore giving less weight to the 
lower and higher values in its range. 
 
For bias due to inadequate or unclear blinding, differences between posterior estimates from fitting 
models with the five different priors are illustrated in Figure 1.   Comparable results were obtained for 
bias due to inadequate or unclear sequence generation and allocation concealment (results not shown).  
The posterior distributions for mean bias b0 and between meta-analysis variance in mean bias φ are 
  
 
fairly robust to the choice of prior for the multiplicative parameter λj  in the model.  Posterior 
estimates for the multiplicative parameter λj are somewhat consistent among the different priors, with 
overlapping credible intervals, but the more precise priors 1, 3 and 5 unsurprisingly lead to lower 
posterior standard deviations for λ3.   
 
7.  Discussion 
 
We have proposed univariable and multivariable label-invariant models for conducting meta-
epidemiological analyses to investigate the influence of a single study characteristic or multiple study 
characteristics on intervention effect and heterogeneity in a meta-analysis.  The label-invariant models 
are modified versions of a model proposed by Welton et al. [2].   When considering heterogeneity 
among effect sizes, our methods allow us to distinguish between variation due to known study 
characteristics and other sources of between-study variation, as recommended by Higgins et al. [16].  
Our label-invariant models are more flexible than the models of Welton et al., in allowing us to 
quantify the ratio by which between-study heterogeneity changes for studies with certain 
characteristics.    
 
We applied the existing additive and proposed label-invariant univariable and multivariable models to 
the ROBES [6] database.  As an example application of the univariable models, we investigated the 
influence of trial sample sizes of less than 100 participants.  As an example application of the 
multivariable models, we investigated the influence of inadequate or unclear sequence generation, 
allocation concealment and blinding.  The findings in these examples give little to choose between the 
additive and label-invariant models; differences between the two models in deviance information 
criterion were small and not very meaningful.  Reassuringly for the meta-epidemiological studies that 
use the additive model of Welton et al. [2], estimates of mean and variance parameters in the model 
were not very sensitive to the way that the meta-epidemiological data were modelled.  However, the 
additive model gave inconsistent results; results for the influence of trial sample size less than 100 
participants showed increased heterogeneity among smaller studies, but after re-labelling the trials to 
investigate the influence of trial sample size at least 100 participants results showed increased 
heterogeneity among larger studies (95% credible intervals did not contain the null value 0).  We 
would therefore propose using the label-invariant model in future meta-epidemiological studies, on 
the grounds that the additive model is less general, and that it would be reasonable to allow 
heterogeneity among studies with a certain characteristic to be higher or lower than that among 
studies without the characteristic. 
 
  
 
Empirical studies have investigated the impact of small studies on meta-analysis results [8;17;18].  
There is empirical evidence to suggest that estimates of intervention effect are exaggerated in smaller 
studies, but little attention has been paid to small study effects on heterogeneity.  Through meta-
epidemiological analyses of the ROBES dataset, we have obtained empirical evidence that trials with 
less than 100 participants are more heterogeneous.  Based on results from fitting our proposed label-
invariant model, variation among trials with sample size less than 100 is, on average, 88% greater 
than that among trials with at least 100 participants.  Exploring estimated heterogeneity among small 
studies should form the subject of future work.  In particular, we have focussed on a dataset 
comprising meta-analyses of binary outcome data, and our results cannot necessarily be generalised to 
meta-analyses of continuous or other outcomes.  Results of meta-epidemiological studies using 
different types of outcome data would be of interest.    
 
In future work we plan to conduct an empirical study of the extent of heterogeneity in a meta-analysis 
that is due to within-study biases.  Our planned empirical study will contribute to our understanding of 
associations between study-level characteristics and the extent of heterogeneity in a meta-analysis.  It 
might occur that a trial characteristic is associated with bias in intervention effect, but that the bias 
does not explain between-trial heterogeneity in the meta-analysis.  In this situation, using the formulae 
of Welton et al. to correct for bias in a new meta-analysis may inappropriately lead to greater down-
weighting of the trials with the characteristic, whereas our label-invariant models may give the trials 
with the characteristic relatively more weight. 
 
In the example applications, we found that the credible intervals obtained for the multiplicative 
parameter λ in our label-invariant model were typically very wide.  This is of concern because the 
estimates of λ are of substantial interest, quantifying the ratio by which between-study heterogeneity 
increases for studies with the characteristic of interest.  We advise caution in interpreting estimates of 
λ, in particular those close to 1 and those for which the lower or upper bound of the credible interval is 
close to 1.  We suggest the use of non-informative priors that exclude implausibly high values in 
analyses of meta-epidemiological data.  In any meta-epidemiological analysis, we recommend 
assessing the sensitivity of results to the choice of prior distributions for unknown parameters, 
particularly when data comprise meta-analyses of only a small number of studies (e.g. fewer than 10).   
 
In summary, we have proposed label-invariant models for meta-epidemiological analyses 
investigating the influence of a single study characteristic or multiple study characteristics on 
intervention effect and heterogeneity.  Unlike existing methods, our approach does not constrain 
between-study heterogeneity to be higher for studies with specific characteristics than for studies 
without the characteristics, and thus facilitates empirical investigations of heterogeneity. 
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Table 1.  Posterior summaries from univariable models with additive and label-invariant variance 
structures, examining the influence of sample size less than 100 participants. 
 Additive model Label-invariant model 
Parameters in model Median SD 95% CI Median SD 95% CI 
b0 -0.16 0.05 -0.25 to -0.07 -0.17 0.04 -0.25 to -0.09 
ROR 0.85 0.04 0.76 to 0.93 0.84 0.04 0.78 to 0.92 
λ  n/a 1.88 0.52 1.08 to 3.10 
κ  0.22 0.11 0.02 to 0.40 n/a 
ϕ  0.22 0.09 0.03 to 0.36 0.19 0.09 0.03 to 0.36 
Predictive distributions for heterogeneity among trials with sample size ≥ 100 in a new meta-analysis 
2
newτ (heterogeneity among 
trials with Xim=0) 
Log-normal(-2.94, 1.692) 
Median=0.05, 
95% range 0.002 to 1.42 
Log-normal(-2.96,1.592) 
Median=0.05, 
95% range 0.002 to 1.13 
Model fit Dres=4183, pD=2838, DIC=7021 Dres=4186, pD=2832, DIC=7018 
SD standard deviation; CI credible interval; b0 average difference in intervention log odds ratio associated with smaller 
sample sizes , ROR average change in estimated intervention effects for smaller trials (ratio of odds ratios); κ average 
increase in between-trial heterogeneity for smaller trials within meta-analyses; λ average change in heterogeneity variance 
for smaller trials; φ between-meta-analysis variance  in the average difference in intervention effect associated with 
smaller sample sizes; Dres posterior mean of the total residual deviance; pD effective number of parameters; DIC deviance 
information criterion. 
 
Table 2.  Posterior summaries from the univariable model with label-invariant variance structure, 
examining the influence of sample size greater than 100 participants. 
 Additive model Label-invariant model 
Parameters in model Median SD 95% CI Median SD 95% CI 
b0 0.16 0.04 0.08 to 0.23 0.17 0.04 0.09 to 0.25 
ROR 1.17 0.04 1.08 to 1.25 1.18 0.05 1.09 to 1.28 
λ  n/a 0.53 0.13 0.32 to 0.85 
κ  0.03 0.02 0.01 to 0.09 n/a 
ϕ  0.24 0.07 0.03 to 0.34 0.20 0.09 0.02 to 0.35 
Model fit Dres=4208, pD=2813, DIC=7021 Dres=4177, pD=2572, DIC=6749 
SD standard deviation; CI credible interval; b0 average difference in intervention log odds ratio associated with larger 
sample sizes , ROR average change in estimated intervention effects for larger trials (ratio of odds ratios); κ average 
increase in between-trial heterogeneity for larger trials within meta-analyses; λ average change in heterogeneity variance 
for larger trials; φ between-meta-analysis variance  in the average difference in intervention effect associated with larger 
sample sizes; Dres posterior mean of the total residual deviance; pD effective number of parameters; DIC deviance 
information criterion. 
  
 
Table 3.  Posterior summaries from the multivariable models with additive and label-invariant 
variance structures, examining the influence of inadequate or unclear sequence generation, allocation 
concealment and blinding. 
 Additive model Label-invariant model 
Parameters in model Median SD 95% CI Median SD 95% CI 
Inadequate or unclear sequence generation 
b01 -0.05 0.05 -0.14 to 0.04 -0.04 0.04 -0.13 to 0.05 
ROR 0.95 0.04 0.87 to 1.04 0.96 0.04 0.88 to 1.05 
1λ  n/a 1.25 0.55 0.56 to 2.71 
1κ  0.12 0.07 0.02 to 0.26 n/a 
1φ  0.14 0.07 0.02 to 0.29 0.15 0.07 0.02 to 0.29 
Inadequate or unclear allocation concealment 
b02 -0.04 0.04 -0.12 to 0.04 -0.04 0.04 -0.12 to 0.04 
ROR 0.96 0.04 0.88 to 1.05 0.96 0.04 0.89 to 1.04 
2λ  n/a 0.77 0.42 0.33 to 1.93 
2κ  0.06 0.05 0.01 to 0.20 n/a 
2φ  0.06 0.05 0.01 to 0.19 0.06 0.05 0.01 to 0.21 
Inadequate or unclear blinding 
b03 -0.09 0.04 -0.17 to -0.01 -0.09 0.04 -0.17 to -0.01 
ROR 0.92 0.04 0.85 to 0.99 0.92 0.04 0.85 to 0.99 
3λ  n/a 1.51 0.63 0.71 to 3.14 
3κ  0.08 0.07 0.01 to 0.27 n/a 
3φ  0.09 0.06 0.01 to 0.23 0.11 0.07 0.01 to 0.25 
Implied average bias in studies judged as inadequate/unclear for all three design characteristics 
b0 -0.18 0.05 -0.28 to -0.08 -0.17 0.05 -0.27 to -0.07 
ROR 0.84 0.04 0.76 to 0.92 0.85 0.04 0.76 to 0.94 
Predictive distributions for heterogeneity remaining after “removing” bias in a new meta-analysis 
2
newτ (heterogeneity among trials with 
Xim=0) 
Log-normal(-3.89,1.842) 
Median=0.02, 
95% range <0.001 to 0.72 
Log-normal(-3.89,1.792) 
Median=0.02, 
95% range <0.001 to 0.65 
Model fit Dres=2962, pD=1922, DIC=4884 Dres=2978, pD=1913, DIC=4891 
SD standard deviation; CI credible interval; b0 average difference in intervention log odds ratio associated with the characteristic, ROR average 
change in estimated intervention effects for trials with the characteristic (ratio of odds ratios); κ average increase in between-trial heterogeneity for 
trials with the characteristic within meta-analyses; λ average change in heterogeneity variance for trials with the characteristic of interest; φ between-
meta-analysis variance  in the average difference in intervention effect associated with the characteristic; Dres posterior mean of the total residual 
deviance; pD effective number of parameters; DIC deviance information criterion. 
 
  
 
 
 
 
Figure 1.  Posterior medians and 95% credible intervals for mean bias due to inadequate/unclear blinding b03, between meta-analysis standard deviation in mean bias φ3, 
and the multiplicative parameter λ3. 
  
 
 
 
